Press Releases April 30, 2026 04:15 PM

Piedmont Realty Trust, Inc. Releases First Quarter 2026 Results

Piedmont Realty Trust reports Q1 2026 financial results and schedules earnings call.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
PDM

Piedmont Realty Trust, a self-managed real estate investment company specializing in Class A office properties in U.S. Sunbelt markets, announced its financial and operational results for Q1 2026. The company has scheduled a conference call and webcast to discuss the quarter's performance and recent developments.

Piedmont Realty Trust, Inc. Releases First Quarter 2026 Results
PDM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Piedmont Realty Trust focuses on ownership and operation of approximately 16 million square feet of Class A office space across key Sunbelt U.S. markets.
  • The company adopts a hospitality-driven approach to enhance workplace environments, branding its properties as 'Piedmont PLACEs'.
  • The firm will hold a conference call and webcast to review first quarter results and address analyst questions.

Atlanta, GA, April 30, 2026 (GLOBE NEWSWIRE) -- Piedmont Realty Trust (NYSE: PDM) has released its financial and operational results for the quarter ended March 31, 2026. Please visit the Investor Relations section of Piedmont's website at https://investor.piedmontreit.com to access the Earnings Release and Supplemental Information.


Piedmont has scheduled a conference call and an audio web cast for Friday, May 1, 2026, at 9:00 a.m. ET during which the Company’s management team will review first quarter performance, discuss recent events, and conduct a question-and-answer period.


To Listen to the Live or Replay of the Webcast:

Click on the webcast link under the Investor Relations section of the Company's website at https://investor.piedmontreit.com/news-and-events/event-calendar


For analysts that are participating in the Conference Call:

Please dial in at least fifteen minutes prior to start time to ensure a timely connection.

Domestic: (888) 506-0062

International: (973) 528-0011

Participant Access Code: 820042

To Listen to the Replay Telephonically: 

Domestic: (877) 481-4010

International: (919) 882-2331 

Replay Passcode: 53839

The playback can be accessed through May 15, 2026.

About Piedmont Realty Trust

Piedmont Realty Trust™ (NYSE: PDM), is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of approximately 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into premier “Piedmont PLACEs” that enhance each client’s workplace experience.


Research Analysts/ Institutional Investors Contact:

770-418-8592

investor.relations@piedmontreit.com

Shareholder Services/Transfer Agent Services Contact:

Computershare, Inc.

866-354-3485

investor.services@piedmontreit.com



Risks

  • Real estate market conditions, particularly in office space, may be impacted by economic downturns or shifting work-from-home trends, affecting occupancy and rental income.
  • Conference calls and guidance may reveal performance weaknesses, which could influence investor sentiment and stock price.
  • Operational risks tied to property management, including maintaining high occupancy and tenant satisfaction, especially in competitive Sunbelt markets.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026